Report a side effect Get study alerts
Find a Trial
A clinician in a white coat speaking with a patient in a clinic room

Home/Areas of Study/Breast Cancer

OncologyPhase I–III

Our commitment to clinical research for breast cancer

Westbridge has developed medicines for life-threatening diseases for more than thirty years. Taking part in a clinical study is a personal decision, and a crucial one. We hope what follows is useful as you think it through.

Find a trial See enrolling studies

~15%

of all breast cancers are triple negative — the subtype with the fewest targeted options today

18 studies in this area

Featured trials

A selection of what is open right now. Eligibility is decided by the investigator at a study site, never by this page.

Recruiting

Metastatic breast cancer: WCS-BC-5763

A Phase 1/2, open-label study of an antibody-drug conjugate given at an alternative dose and schedule in participants with advanced disease.

Studies open and close continually. We can text you when a new one opens near you.

Get study alerts

Our research

What are we studying?

Learn more about our areas of research and see whether one of our clinical trials might be right for you.

HR+/HER2− breast cancer

  • Breast cancer cells carry receptors that respond to hormones such as oestrogen and progesterone, or to proteins such as human epidermal growth factor.
  • Growth is driven by those hormones or proteins, so treatment is chosen by receptor type and may combine chemotherapy, hormone therapy, surgery or radiation.
  • Around 69% of all breast cancers are hormone receptor positive and HER2 negative.

Triple negative breast cancer (TNBC)

  • TNBC is diagnosed when cancer cells test negative for oestrogen, progesterone and human epidermal growth factor receptor 2.
  • It accounts for roughly 15% of breast cancers.
  • It is an aggressive form and disproportionately affects Black women, which is why recruitment for these studies is designed with that in mind.

Want to understand what taking part actually involves before you go further?

Read the guide